No registrations found.
ID
Source
Brief title
Health condition
NSCLC niet kleincellig longcarcinoom, longkanker
lungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor cel
Sponsors and support
Intervention
Outcome measures
Primary outcome
- heterogeneity and mutational load measurements in all compartments. These can subsequently be compared to one another.
Secondary outcome
-
Study objective
NSCLC spreads using the blood. Tumour cells in the circulating system are called circulating tumour cells, and are deemed the cause of metastases, making CTCs a mayor factor in therapy efficacy and prognosis. We believe that the different compartments (original tumour, metastases and CTCs) will have differences in the genetic make up that could give insight in the metastatic process and shed light on so called 'trunc' and 'branch' mutations. To study all different compartments in detail, we will ask terminal patients to participate in a so called obduction study. After a patients death, we will obtain biopsies of the metastases and the primary tumour. When this is done the patients body will be returned to the family for burial.
Study design
-
Intervention
Terminal patients are included after their informed consent and that of their families is received. We will withdraw some blood for analysis on CTCs. After the participants death, we will perform a warm autopsy to obtain samples from the primary tumour and its metastases. The patients body will subsequently be returned to the family for burial.
Department of Pulmonary Disease, Box 30001
H.J.M. Groen
Groningen 9700 RB
The Netherlands
+31 (0)50 3616161
h.j.m.groen@int.umcg.nl
Department of Pulmonary Disease, Box 30001
H.J.M. Groen
Groningen 9700 RB
The Netherlands
+31 (0)50 3616161
h.j.m.groen@int.umcg.nl
Inclusion criteria
1. Patients with a histologically/cytologically proven pulmonary malignancy.
2. Patients have to have a non-curable disease state, without curative treatment options
3. Signed informed consent
4. Patients family has asserted their acceptance of the patients participation
5. Patients using anticoagulants such as fraxodi or acenocoumarol are allowed
Exclusion criteria
1. No growth factor medication
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL5862 |
| NTR-old | NTR6042 |
| CCMO | NL59037.042.16 |
| OMON | NL-OMON45251 |